Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT04601857
Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma
- NCT04601857 ↗
- Terminated
- Taiho Oncology, Inc.
- Focused
We haven't built an HCP commentary report on NCT04601857 (futibatinib plus pembrolizumab in advanced or metastatic urothelial carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT04601857 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| YouTube | 2 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2 Study Evaluating Futibatinib (TAS 120) Plus Pembrolizumab in the Treatment of Advanced or Metastatic Urothelial Carcinoma
- Phase
- Phase 2
- Status
- Terminated
- Conditions
- Advanced and Metastatic Urothelial Cancer
- Interventions
- Futibatinib; Pembrolizumab
- Arms
- Cohort A · Experimental
- Cohort B · Experimental
- Enrollment
- 43
- Primary outcomes
- Objective Response Rate (ORR)
- Sponsor
- Taiho Oncology, Inc. with Merck Sharp & Dohme LLC
- Start
- Jan 7, 2021
- Primary completion
- Mar 8, 2024
- Results posted
- Yes
- Registry record
- NCT04601857 · updated Dec 31, 2025